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http://dx.doi.org/10.1016/j.ccell.2015.03.005SUMMARYTherapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging
the immune system. Unfortunately, cures rarely occur and patients display intrinsic or acquired resistance.
Here, we demonstrate the therapeutic potential of targeting human (h) FcgRIIB (CD32B), a receptor
implicated in immune cell desensitization and tumor cell resistance. FcgRIIB-blocking antibodies prevented
internalization of the CD20-specific antibody rituximab, thereby maximizing cell surface accessibility and
immune effector cell mediated antitumor activity. In hFcgRIIB-transgenic (Tg) mice, FcgRIIB-blocking
antibodies effectively deleted target cells in combination with rituximab, and other therapeutic antibodies,
from resistance-prone stromal compartments. Similar efficacy was seen in primary human tumor xenografts,
including with cells from patients with relapsed/refractory disease. These data support the further develop-
ment of hFcgRIIB antibodies for clinical assessment.INTRODUCTION
Biological therapies, and monoclonal antibodies (mAbs) in
particular, are an expanding class of therapeutics (Reichert
and Dhimolea, 2012). They have revolutionized cancer therapy
and become standard of care alongside conventional chemo-Significance
Therapeutic antibodies have improved cancer treatment, but r
ure. Antibodies exert antitumor activity by interferingwith ligan
patient anti-cancer immunity through interaction with immune
receptor expressed on immune cells and certain cancers, Fc
resistance and treatment failure in lymphoma and leukemia. W
human FcgRIIB overcome this resistance. By blocking FcgRIIB
ically approved therapeutic mAbs and overcame relapsed/ref
come cancer cell resistance and improve clinical responses wtherapy for several malignancies. Their activity is governed by
interaction with Fc gamma receptors (FcgR). Specifically, the
relative expression level, affinity, and activity of the FcgR ex-
plains much of their efficacy (Nimmerjahn and Ravetch, 2008,
2011). Much less is known of the mechanisms underlying
intrinsic or acquired resistance to mAbs. With mAb therapiesesistance frequently emerges translating into treatment fail-
d-receptor signaling pathways and uniquely by orchestrating
cell antibody receptors (FcgRs). A single inhibitory antibody
gRIIB, is implicated in intrinsic and acquired antibody drug
e demonstrate that monoclonal antibodies (mAbs) targeting
function, thesemAbs augmented the activity of several clin-
ractory disease in vivo. Targeting FcgRIIB could help over-
ith multiple mAb therapies.
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Figure 1. Therapeutic Effects of hFcgRII mAb (AT10) and Generation of Specific mAbs Capable of Distinguishing hFcgRIIB and hFcgRIIA
(A) SCIDmice (five per group) xenografted with Daudi cells (s.c.) were treated (i.p.) as indicated by arrows. Mean tumor weights plotted ± SEM and analyzed using
unpaired t test; p values compare rituximab (Rit) alone versus Rit + AT10-treated groups (**p% 0.005). Representative data (n = 2).
(legend continued on next page)
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increasingly being developed, there is an urgent need to under-
stand resistance and to develop drugs to overcome it. Because
several anti-cancer mAbs depend on engaging mAb-dependent
immune cell-mediated anti-tumor mechanisms for preclinical
(Beers et al., 2010; Clynes et al., 2000; Hamaguchi et al., 2006;
Minard-Colin et al., 2008) and clinical efficacy (Cartron et al.,
2002; Dyer et al., 1989; Weng and Levy, 2003), there is a need
to understand and prevent resistance to them.
Rituximab is a type I hCD20 mAb approved for cancer immu-
notherapy and has been widely administered to patients with B
cell cancers including follicular lymphoma (FL), diffuse large
cell B cell lymphoma (DLBCL), chronic lymphocytic leukemia
(CLL), and mantle cell lymphoma (MCL) (Lim et al., 2010).
Whereas rituximab is efficacious in FL and DLBCL, improving
overall survival, only modest responses are seen in CLL and
MCL. Furthermore, even with rituximab-responsive lymphoma
sub-types, some individuals show initial resistance or subse-
quently develop it, making it a clinically relevant system in which
to study mAb resistance mechanisms.
We recently demonstrated that the inhibitory FcgRIIB pro-
motes rituximab internalization from B cells (Lim et al., 2011;
Vaughan et al., 2014). As the main IgG receptor on B cells,
FcgRIIB becomes phosphorylated and removes rituximab from
the B cell surface, effectively abrogating all mAb-dependent im-
mune cell anti-cancer mechanisms (Lim et al., 2011). In contrast,
so-called type II anti-CD20 mAbs such as the recently approved
obinutuzumab (GA101) are not as sensitive to this process,
perhaps due to their inability to redistribute CD20 into lipid rafts
(Cragg et al., 2003; Lim et al., 2011). FcgRIIB-mediated rituximab
internalization correlated with clinical responsiveness (least to
most) as CLL < MCL < FL and DLBCL (Lim et al., 2011). In keep-
ing with a role for FcgRIIB in mAb resistance, a retrospective
analysis of patients with MCL treated with rituximab immuno-
chemotherapy demonstrated greater survival among patients
with FcgRIIB-negative compared with FcgRIIB-positive tumor
biopsies (Lim et al., 2011). Similarly poor responses were
observed in patients with FL expressing high levels of FcgRIIB
when receiving rituximab monotherapy (Lee et al., 2015).
In this study, we investigate the development of specific mAbs
to hFcgRIIB, capable of blocking rituximab internalization, and
assess their therapeutic potential.
RESULTS
Generation and Characterization of
hFcgRIIB-Specific mAb
We recently reported that resistance to rituximab in some pa-
tients with lymphoma could be explained by its internalization
from the tumor and that the expression of the inhibitory FcgRIIB
on the target B cell surface promotes this process (Beers et al.,
2010; Lim et al., 2011). Consistent with this hypothesis, in vivo(B) scFv screening for binding to hFcgRIIB (yellow dots) and/or hFcgRIIA (blue).
(C) hFcgRIIB mAb binding to hFcgRIIB- (red line) or hFcgRIIA-transfected cells (b
cells (green line).
(D) Binding profile of mAbs on human leukocyte populations.
(E) Dose-dependent binding of mAbs to B cells.
(F) BIAcore assessment of hFcgRIIB mAb binding to hFcgRIIB fusion protein. KD
See also Figure S1 and Table S1.co-administration of hFcgRII mAb AT10 with rituximab resulted
in additive/synergistic anti-tumor responses in two different
lymphoma xenograft models where hCD20 and hFcgRIIB are
co-expressed on the tumors (Figures 1A, S1A, and S1B).
The extracellular domain of hFcgRIIB is 93% homologous
to hFcgRIIA, a key activatory FcgR (Figure S1C). Because
these receptors mediate opposing functions, it is critical for a
therapeutic mAb to be highly specific for hFcgRIIB. AT10
does not fulfill this criterion because it binds both hFcgRIIA
and hFcgRIIB (Greenman et al., 1991). To generate hFcgRIIB-
specific antibodies with therapeutic potential in humans, we
used a human antibody phage-display library n-CoDeR (So¨der-
lind et al., 2000) panning for binding to hFcgRIIB and against
binding to hFcgRIIA (or vice versa) to generate mono-specific
reagents (Figures 1B–1F). The resultant mAbs were assessed
for the ability to selectively bind (Figure 1B) and block
immune complex (IC) binding to hFcgRIIB, but not hFcgRIIA
(Figure 1C). Leukocyte subset (neutrophils, monocytes, B cells,
T cells, and natural killer [NK] cells) screening demonstrated
the high specificity of the mAbs for either hFcgRIIB or hFcgRIIA
(Figures 1D, 1E, and S1D–S1F). The relative affinities for
hFcgRIIB were determined by ELISA (Table S1), with a subset
assessed by surface plasmon resonance (SPR) showing KD for
binding to hFcgRIIB in the range of 1 3 107 to 2 3 108 M
(Figure 1F and Table S1). Accordingly, 14 highly specific
hFcgRIIB mAbs were identified and validated. Although the
fine specificity for each mAb has not been defined, they all
block IC binding and do not cross-react with FcgRIIA, strongly
indicating they bind around the IgG binding cleft, where a high
concentration of residues differing between FcgRIIA and B occur
(Figure S1C).
Antagonistic hFcgRIIB mAbs Block Rituximab
Internalization
Rituximab engagement on B cells activates hFcgRIIB by phos-
phorylating its ITIM (Lim et al., 2011; Vaughan et al., 2014).
We speculated, based on the immune inhibitory function of
hFcgRIIB, that mAbs capable of preventing both CD20 internal-
ization and blocking hFcgRIIB activation/phosphorylation would
be of therapeutic interest. To assess effects in a variable domain-
dependent manner, we engineered N297Q variants that cannot
bind FcgR through their Fc domain (see below) (Tao and Morri-
son, 1989). Treatment of Raji cells with hFcgRIIB mAbs resulted
in two different responses; high levels of ITIM phosphorylation
(e.g., 5C04 and 6G08) and little to no effect (e.g., 6G11 and
7C07) (Figure 2A). Similar observations were seen with primary
CLL cells, tonsils, and monocytes (Figures S2A and S2B,
and data not shown). The varied ability of these mAbs to activate
hFcgRIIB is extremely interesting; the epitopes engaged,
membrane dynamics and structure:function relationships
involved are the focus of our ongoing studies. Nonetheless,lue line) and mAb-dependent inhibition of IC binding to hFcgRIIB-transfected
values calculated from the 1:1 binding model (see Table S1).
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Figure 2. hFcgRIIB mAbs Are Capable of Blocking Rituximab Engagement with FcgRIIB on the Surface of Target Cells
(A) Ability of N297Q hFcgRIIB mAbs to elicit hFcgRIIB ITIM phosphorylation (pFcgRIIB) on Raji cells; hIgG1 isotype control (iso ctrl) and Rit used as negative and
positive controls, respectively. a-Tubulin loading control.
(B) Ability of N297Q hFcgRIIB mAbs to block hFcgRIIB ITIM phosphorylation induced by Rit. Representative blots (n = 3) shown in (A) and (B).
(C) Ability of N297Q hFcgRIIB mAbs to block internalization induced by Rit. Mean + SD of three independent experiments.
(D) Correlation between the ability of hFcgRIIB mAbs to block Rit internalization (shown in C) and their relative ranked affinities (R2 = 0.78).
(E) Correlation between the ability to block Rit internalization and the ability to block Rit-induced phosphorylation of hFcgRIIB (shown in B) (R2 = 0.79).
See also Figure S2.
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the data demonstrate that hFcgRIIB mAbs capable of blocking
IC binding without activating the receptor were successfully
generated.
Next, we investigated whether hFcgRIIB mAbs could block
the interaction between hFcgRIIB and rituximab and prevent
rituximab internalization. Some mAbs such as 6G08 remained
agonistic, stimulating receptor phosphorylation. In contrast,
two mAbs (6G11 and 7C07) referred hereon as antagonistic
were able to almost completely prevent the hFcgRIIB phosphor-
ylation induced after rituximab binding (Figure 2B). The same
mAbs were able to efficiently block internalization of rituximab
from the surface of hFcgRIIB-transfected Ramos cells, similar
to the level seen with the type II hCD20 mAb tositumomab and
Ramos cells lacking hFcgRIIB (Figure 2C). Both wild-type (WT)
and N297Q variants had equivalent activity, indicating a variable
domain dependent effect (Figure S2C) and that antagonistic
effects were retained with WT hIgG1. The ability to block
rituximab internalization correlated with their relative affinity for
hFcgRIIB; R2 = 0.78 (Figure 2D), which was in turn correlated
to their relative ability to block hFcgRIIB phosphorylation after
rituximab stimulation; R2 = 0.79 (Figure 2E). Thus, high-affinity
antagonistic hFcgRIIB mAbs prevented hFcgRIIB-mediated
removal of rituximab from the target cell surface.
Antagonistic hFcgRIIB mAb Have Potent Anti-Tumor
Activity In Vitro
The finding that the antagonistic effects of some mAbs were
retained in the WT hIgG1 format, which productively engages
with activatory FcgR-expressing immune cells, suggested that
these mAbs might have intrinsic Fc:FcgR-dependent anti-tumor
activity. We therefore screened our hFcgRIIB mAbs for such
effects. The antagonistic mAbs 7C07 and 6G11 were among
the clones that induced the highest antibody-dependent cellular
cytotoxicity (ADCC) activity (Figures S3A and S3B). Having
established that these two clones had the highest affinity, and
strongest activity in blocking rituximab internalization and in
eliciting ADCC, we next assessed their binding to a panel of
human and animal tissues known to express FcgRs. Both
7C07 and 6G11 specifically stained lymphocytes in human
spleen and tonsils, but not lymphocytes in cynomolgus mon-
keys, rats, rabbits, or mice indicating that these mAbs are not
cross-reactive for FcgRIIB in other species (Figure 3A and data
not shown). However, clone 7C07, but not 6G11, additionally
stained the sinusoids of spleen and LN from various species,
indicating an undesired cross-reactivity (Figures 3A and S3C).
WT and N297Q 6G11 mAbs were shown to stain equivalently
(Figure S3D), and no additional unanticipated cross-reactivity
was observed on other human tissues (Figure S3E). Based
on this reactivity profile, clone 6G11 was selected as our lead
clinical candidate.
The intrinsic cytotoxic activity of 6G11 was further explored
in programmed cell death (PCD), antibody-dependent cell
phagocytosis (ADCP), and ADCC assays using primary patient
CLL samples. Substantial activity was demonstrated in each
assay at a level greater than observed with rituximab (Figures
3B–3D). Furthermore, 6G11 was more efficacious compared
to rituximab in assays with NK cell effectors expressing either
the high- or low-affinity variants of hFcgRIIIA (158V or F, respec-
tively; Ravetch and Perussia, 1989) (Figure 3E).Subsequently, we examined the ability of 6G11 to prevent
the internalization of rituximab from the surface of primary
CLL cells. Both WT and N297Q (the latter devoid of intrinsic
Fc-dependent effector activity due to an inability to engage
FcgR; Figure S3F) variants of 6G11 prevented rituximab inter-
nalization (Figure 3F). Unlike hCD20, engagement of hFcgRIIB
by either WT or N297Q mAbs (6G11 and AT10) did not result
in high levels of hFcgRIIB internalization (Figures 3G, S3G,
and S3H).
To address whether 6G11 could also enhance the cytotoxic
activity of rituximab by preventing its internalization, we co-incu-
bated primary CLL cells with rituximab and N297Q 6G11 and
assessed ADCP and ADCC. N297Q 6G11 was shown to sub-
stantially promote the ADCP of rituximab-opsonized CLL cells
compared to rituximab alone (Figures 3H and 3I). In these as-
says, there is no free N297Q 6G11 to bind to the macrophage
FcgRIIB, and the N297Q mutation ensures that the Fc region
of 6G11 does not interact with the activatory macrophage
FcgRs. Similar increases in activity were seen in ADCC assays
with NK cells (Figure 3J). NK cells do not express FcgRIIB,
confirming that augmentation through hFcgRIIB mAb arises
from inhibition of rituximab internalization. These data confirm
that blocking hFcgRIIB on the target cell surface inhibits inter-
nalization of the mAb:target:hFcgRIIB complex, and augments
their deletion by effector cells.
Taken together, these observations suggested that 6G11
can elicit anti-tumor activity through dual mechanisms—intrinsic
cytotoxic activity, and potentiation of rituximab activity through
prevention of its removal from the cell surface.
6G11 Is Well Tolerated, Has Therapeutically
Relevant Pharmacokinetics, and Does Not Result
in a Cytokine Storm
hFcgRIIB is expressed on both target B cells, where it mediates
removal of rituximab from the cell surface, and on key immune
effector cells such as macrophages where it dampens anti-
cancer mAb responses (Clynes et al., 2000; Hamaguchi et al.,
2006; Minard-Colin et al., 2008; Montalvao et al., 2013). To
understand the impact of targeting hFcgRIIB systemically on
relevant hFcgRIIB-expressing cell-types, we generated mice
expressing hFcgRIIB under the control of the native human
FCGR2B promoter (Figures S4A and S4B). The expression
and distribution of hFcgRIIB in the Tg mouse closely resembles
that in human tissues being strongly expressed on B lympho-
cytes, less so on macrophages and monocytes and little to
no expression on neutrophils, unlike mouse (m) FcgRII (Figures
S4C–S4G and data not shown). Equivalent expression was
maintained in the Fcgr2b/ mouse background (hereon
mFcgRII/), allowing us to study the effect of hFcgRIIB in
the absence of the endogenous mouse receptor. Importantly,
the antagonistic activity of 6G11 was retained in these mice
(Figure S4H). In addition, hFcgRIIB expression on endothelial
cells was lower than that in WT mice and more similar to
that in humans (Figure S4I; Alison L. Tutt, S.A.J., Ste´phanie
A. Laversin, Thomas R.W. Tipton, M.A.K., Ruth R. French,
K.H., A.T.V., Lang Dou, Alexander Earley, Lekh N. Dahal,
Chen Lu, Melanie Dunscombe, H.T.C.C., Christine A. Penfold,
Jinny H. Kim, Elizabeth Potter, C.I.M., A.R., R.J.O., K.L.C.,
I.T., B.F., M.J.G., S.A.B., and M.S.C., unpublished data).Cancer Cell 27, 473–488, April 13, 2015 ª2015 Elsevier Inc. 477
(legend on next page)
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To ascertain the safety of 6G11 treatment in vivo, we
performed a dose-escalation study treating cohorts of
hFcgRIIB+/ 3 mFcgRII/ mice with 1, 10, or 100 mg/kg
6G11 (Figure S4J). None of the treated mice suffered adverse
events such as acute effects, distress, or weight loss (Fig-
ure S4K). Tissue examination at day 7 failed to indicate any gross
toxicity in the organs (kidney, brain, spleen, liver, lungs). Sub-
stantial depletion of hFcgRIIB+ B cells was observed both in
the blood (Figure 4A) and spleen (Figure 4B) at doses above
1mg/kg, with equivalent activity in the 10 and 100mg/kg groups.
6G11 is a fully human mAb easily detected in the sera of mice
but inherently immunogenic, so we concurrently assessed its
half-life and evidence of mouse anti-human antibody (MAHA)
responses. At doses >1 mg/kg, target-mediated clearance
that affects the pharmacokinetic (PK) profile was overcome,
with little or no effect of target binding in the 10 and 100 mg/kg
groups (Figure 4C). However, within 7 days, significant MAHA
was observed, resulting in rapid mAb clearance (Figure 4D).
Based upon the time-points prior to the advent of significant
MAHA, we estimate the mAb half-life to be in the region of
2–4 days for the 10 and 100 mg/kg doses (Figures 4C and 4D
and Table S2).
We also performed a repeat dosing study to better mimic how
6G11 might be delivered clinically, administering it four times
throughout a 24-day period (Figure S4L) with mice examined
as before. Depletion of circulating B cells was observed in
hFcgRIIB+/3mFcgRII/ but not themFcgRII/ control group
injectedwithmultiple doses (10mg/kg) of 6G11 (Figure 4E). Like-
wise, mice did not suffer weight loss (Figure S4M) or adverse
events and no signs of gross toxicity were observed (data not
shown). As before, substantial MAHA responses were observed
in hFcgRIIB+/ 3 mFcgRII/ mice within 1 week and contrib-
uted to rapid loss of 6G11 from the serum (Figure 4F). In contrast,
no MAHA was detected in the mFcgRII/ control group,
indicating a co-dependence on xenogeneic mAb and surface
antigen being required for MAHA induction (Figure 4F).
To explore if hFcgRIIB+ cells other than B cells might be
deleted after 6G11 treatment, whole blood depletion assays
with human blood (Figures 4G–4I) and in vivo experiments with
the hFcgRIIB Tg mice (Figure S4N) were performed. B cells but
not monocytes or neutrophils were deleted by WT 6G11 IgG1,
but not N297Q 6G11. The same lack of depletion of monocytes
and neutrophils was seen in combination with rituximab (Figures
4G–4I). Next, we used a recently developed in vitro cytokineFigure 3. hFcgRIIBmAb 6G11Has Potent Cytotoxic Activity In Vitro and
of CLL Cells
(A) IHC analysis of spleen tissues using 7C07 and 6G11.
(B–D) Cytotoxic ability of 6G11 in PCD (B), ADCP (C), and ADCC (D) using prima
(E) ADCC assay using effector cells expressing the hFcgRIIIA 158F or V allele; me
concentrations.
(B–E) In all graphs, the iso ctrl values have been subtracted.
(F) Ability of 6G11 to impair Rit internalization from the surface of CLL cells (n = 6
(G) Ability of 6G11 to remain at the surface of CLL cells (n = 6).
(F and G) Box-and-whisker plots indicating the upper and lower quartiles with the
and minimum values. Data analyzed using Wilcoxon test.
(H and I) CFSE-labeled CLL cells opsonized for 3–4 hr with Rit ± N297Q iso ctrl or
the % of MDMs that have phagocytosed CFSE+ CLL cells in (I).
(J) CLL cells opsonized with Rit ± N297Q iso ctrl or 6G11 for 3–4 hr before co-cu
(B–D, I, and J) Mean values shown (horizontal lines) with each dot representing arelease syndrome (CRS) assay (CRA) (Hussain et al., 2015) to
assess the potential impact of 6G11 on human peripheral blood
mononuclear cells (PBMCs) rendered sensitive to stimulation
through high-density culture (Ro¨mer et al., 2011) and detected
substantial levels of interferon gamma, tumor necrosis factor
alpha and/or interleukin 8 following addition of several mAb
specificities (CD3, CD28, or CD52) previously highlighted as
eliciting CRS. Application of WT or N297Q 6G11 for 48 hr did
not result in substantial cytokine release, unlike with 5003 lower
doses of CD3 mAb (Figure 4J). Similar results were obtained
using a whole or diluted blood CRA (Figure S4O).
Collectively, these data demonstrated no adverse effects and
indicated a therapeutically relevant PK profile for 6G11 mAb,
supporting efficacy studies.
6G11 Has Intrinsic Activity and Potentiates Depletion
with Rituximab in Immune-Competent Mice
The depleting potential of targeting hFcgRIIB, alone or in combi-
nation with rituximab, was then assessed using both 6G11
(hIgG1) and AT10 (mIgG1). First, in short-term adoptive transfer
assays, where CFSE+ hFcgRIIB+/ 3 mFcgRII/ splenocytes
were injected into WT recipients and subsequently treated with
6G11 (Figures 5A and 5B) or AT10 (Figure S5A), transferred cells
were observed to be efficiently depleted from the circulation and
spleen. As little as 0.04 mg/kg mAb was sufficient to elicit50%
B cell depletion. Depletion was dependent upon Fc:activatory
FcgR interaction as activity was lost with F(ab0)2 fragments
and N297Q variants; hFcgRIIB+ targets were also not deleted
in g chain/ (gKO) mice, lacking activatory FcgRs (Figures 5A,
5B, and S5A). These data confirm that 6G11 is capable of
deleting target cells in vivo, dependent upon the interaction
with activatory FcgRs on immune effector cells.
To extend our analysis to combination therapy with rituximab,
hCD20+/ 3 hFcgRIIB+/ 3 mFcgRII/ mice were generated.
Combination of rituximab and 6G11 (or AT10) resulted in
higher depletion of target B cells compared to either mAb
alone in assays transferring targets into WT recipients (Figures
5C and S5B, respectively). Similarly, adoptively transferred
hCD20+/ 3 hFcgRIIB+/ 3 mFcgRII/ B cells were more
effectively depleted by combining rituximab with 6G11 in
hFcgRIIB+/ 3 mFcgRII/ recipient mice (expressing the
hFcgRIIB also on the effector cells) (Figure 5D). As above, treated
mice did not suffer weight loss, did not appear to suffer adverse
events, and no signs of gross toxicity were observed.Is Capable of Blocking Rit Engagement with hFcgRIIB on the Surface
ry CLL cells.
an ± SD (n = 3). Data analyzed with t test comparing samples at the indicated
).
median shown as the horizontal line and the whiskers showing the maximum
6G11 before co-culture with MDMs. Representative dot plots shown in (H) and
lture with NK cells.
n individual donor. Data analyzed by paired t test. See also Figure S3.
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We next investigated the effect of the combination on circula-
tory B cells in the hCD20+/ 3 hFcgRIIB+/ 3 mFcgRII/
mouse. As before, the combination resulted in significantly
greater depletion of circulating B cells compared to monother-
apy (Figures 5E, 5F, S5C, and S5D), demonstrating this capacity
in a fully syngeneic system in which hFcgRIIB is expressed on
both the target and effector cells. The effect of combining ritux-
imab and WT hIgG1 6G11 (or AT10) was greater than that ex-
pected for additive activity (Figures 5F, left/upper, and S5D,
respectively), as judged from the responses observed with the
individual mAbs applied singly at 2-fold higher doses.
To assess whether intrinsic (B cell depleting) versus extrinsic
(rituximab boosting) effects of 6G11 were more important
for this activity, we used N297Q 6G11 in the hCD20+/ 3
hFcgRIIB+/ 3 mFcgRII/ mice and show that, although
N297Q 6G11 alone is inactive in deletion, it significantly boosts
rituximab deletion of B cells (Figure 5F, upper). Similar results
were seen with mIgG1 6G11. As expected and observed with
AT10 (Figure S5D), mIgG1 6G11 displayed poor single agent
depleting activity in hCD20+/ 3 hFcgRIIB+/ 3 mFcgRII/
mice (Hamaguchi et al., 2006), but similar to N297Q hIgG1
6G11, was able to significantly boost a murine IgG2a version
of rituximab in its ability to deplete B cells (Figure 5F, lower).
Moreover, owing to its mouse Fc, it is not actively cleared by
MAHAs, facilitating longer-term assessment of the combination
therapy. These data show the long-term beneficial effect
of antagonizing hFcgRIIB-function for enhancing rituximab’s
depleting activity in vivo.
Together, these studies confirmed a dual mechanism of action
for 6G11 in vivo, involving intrinsic anti-tumor function coupled
to the potentiation of rituximab anti-tumor activity through the
prevention of internalization.
6G11 Boosts Rituximab-Mediated Depletion of Primary
CLL Cells and Improves Objective and Complete
Responses In Vivo
To better assess the anti-tumor activity of 6G11 against
CLL cells, we developed a mouse model where primary human
CLL cells home to lymphoid organs (spleen and bone marrow),
and proliferate in clusters alongside supportive human T cells,
thereby mimicking the situation in humans (Figures 6A and 6B).
In this model, rituximab is highly effective at depleting CLL cells
residing in the peritoneal cavity, but not the splenic proliferation
centers (Figure S6A).
Mice treated with either rituximab or 6G11 alone showed
significant reductions in the number of tumor cells in the spleenFigure 4. hFcgRIIB mAb 6G11 Is Well Tolerated and Does Not Result in
(A–D) hFcgRIIB+/ 3 mFcgRII/ mice (six to seven mice/group) were injecte
(A, normalized to pre-dose) and the number of splenic B cells (B, expressed as th
6G11 concentrations (C) and MAHA titers (D) were assessed at the indicated tim
(E and F) hFcgRIIB+/ 3mFcgRII/ (n = 6) or mFcgRII/ mice (n = 3) were injec
(E) and MAHA titers (F) were assessed. Results are shown as mean ± SD. Data w
pre- versus post-treatment or untreated versus treated groups, respectively.
(G–I) In vitro whole blood depletion assay to assess potency of Rit ±WT or N297Q
Mean values shown (horizontal lines) with each dot representing an individual do
(J) Cytokine response assessment using pre-cultured PBMCs left untreated (NT) o
used as a positive control at optimal and sub-optimal concentrations. Supernatan
ANOVA.
See also Figure S4 and Table S2.compared to isotype control treated mice. Whereas rituximab
and 6G11 monotherapy yielded comparable results, combina-
tion therapy with rituximab and 6G11 was considerably more
efficacious and statistically significant (Figures 6C and S6B
and Table S3). Additionally, the numbers of objective- (OR;
defined as >75% reduction of CLL cells in the spleen) and com-
plete responders (CR; defined as <0.1% CLL cells in the spleen)
following combination therapy were significantly higher than
isotype control-treated mice or monotherapies (Figure 6C,
bottom; Table 1). These data demonstrate the increased efficacy
of the rituximab/6G11 combination therapy against primary
CLL cells in vivo.
We then examined the ability of 6G11 to treat mice engrafted
with CLL cells isolated from rituximab, ofatumumab (hCD20
mAb), and/or alemtuzumab (hCD52 mAb)-refractory patients
(Table S4). The xenografted mice were treated with either
6G11 or rituximab as monotherapy, or with the two mAbs in
combination. As expected, treatment with rituximab alone was
inefficient (Figures 6D and S6C and Table S3) and >95% of
mice failed to generate OR. In contrast, 6G11 alone showed
significant CLL cell depletion, but failed to improveOR (Figure 6D
bottom; and Table 1). Remarkably, however, co-administration
of rituximab with 6G11 resulted in robust depletion (Figure 6D
and Table S3) with >25% OR (Table 1). These data suggest
that, in addition to boosting rituximab activity in responder
patients, 6G11 may be active against treatment-refractory
CLL cells.
Combination Therapy Has Activity against MCL
Cells In Vivo
To evaluate the ability of 6G11 to target other types of malignant
B cells, we used immunodeficient mice engrafted with Jeko or
primary MCL cells. Monotherapy with either 6G11 or rituximab
did not result in long-term survival in mice engrafted with
Jeko cells, whereas 30% of mice treated with the combination
survived tumor-free out to 100 days (Figure S6D). Primary
MCL cells also responded favorably to combination therapy
(Figure S6E and Table S3).
6G11 Enhances Therapeutic Activity of other Clinically
Relevant Antibodies In Vivo
Recent observations indicate that FcgRIIB-dependent inter-
nalization may underlie resistance to several clinically relevant
antibodies besides rituximab (Vaughan et al., 2014;Pallasch
et al., 2014). We therefore examined combining 6G11 with
the recently approved hCD20 mAb obinutuzumab (GA101),Toxicity
d with 6G11. The percentage of circulating CD19+ B220+ B cells assessed
e percentage of splenic lymphocytes) were quantified on day 7 whereas serum
es. Results are shown as mean + SD.
ted with WT 6G11 (i.v.), followed by serial i.p. injections and circulating B cells
ere analyzed using paired (A and E) and unpaired t tests (B); p values compare
6G11 in depleting hFcgRIIB+ blood B cells (G), monocytes (H), or neutrophils (I).
nor.
r treated with WT or N297Q variants of iso ctrl or 6G11. CD3mAb (clone OKT3)
t cytokines assessed by MSD (mean + SD; n = 3); data analyzed using one-way
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and the clinically well-validated hCD52 specific mAb alemtuzu-
mab. The specificity of obinutuzumab for hCD20 allowed us
to study effects in the syngeneic mouse model. Both GA101
and 6G11 monotherapy resulted in modest depletion of
splenic and circulating B cells, whereas the combination signifi-
cantly enhanced depletion in WT (Figures 6E and S6F) and
hFcgRIIB+/ 3 mFcgRII/ mice (Figures 6F and S6G).
Combining 6G11 with GA101 significantly improved splenic
tumor cell depletion in the CLL-patient xenograft mouse model
(Figure 6G; Tables 1 and S3). Whereas alemtuzumab’s speci-
ficity for hCD52 precluded studies in the syngeneic hCD20
model, there was a significant improvement in therapeutic
activity when 6G11 and alemtuzumab were combined in the
CLL-mouse model, with >90% of combination-treated mice
developing CR (Figure 6H; Tables 1 and S3).
These data provide evidence that 6G11 may overcome mAb
drug resistance for multiple targets.
DISCUSSION
Cancer cells are highly proliferative, and genomically unstable
with a high propensity for mutation, allowing drug-resistant
clones to emerge after anti-cancer drug therapy, translating
into treatment failure. It is now well established that tumors influ-
ence their microenvironment, subverting stromal and myeloid
cells to further contribute to resistance and therapy failure (Hana-
han and Weinberg, 2011). Through their ability to engage the
patients’ immune defense mechanisms, mAbs are important
tools in contemporary cancer therapy (Weiner et al., 2010) and
comprise a rapidly expanding class of drugs. Since the approval
of rituximab in 1997, and the recent approval of ofatumumab
and obinutuzumab (Lim et al., 2010), these agents have become
central to the armamentarium for treating cancer. However, it is
clear that mAb immunotherapy is also susceptible to both
intrinsic and acquired resistance (Bardelli and Siena, 2010;
Montagut et al., 2012; Rampias et al., 2014; Rezvani and Malo-
ney, 2011; Wong and Lee, 2012).
At least two mechanisms of resistance, which may affect
numerous therapeutic mAbs, are precipitated by the inhibitory
FcgRIIB (Williams et al., 2013a). In addition to the inhibitory
effect on effector cells (Clynes et al., 2000), rituximab and other
type I hCD20 mAbs engage hFcgRIIB by bipolar antibodyFigure 5. hFcgRIIB mAb 6G11 Is Active In Vivo and Potentiates CD20 m
(A and B) hFcgRIIB+/ 3 mFcgRII/ target and mFcgRII/ non-target spleno
transferred intoWT or gKO recipient mice. Mice receivedWT or N297Q (NQ) 6G11
the ratio of CD19+ target: non-target cells remaining; normalized to ctrl group (NT)
(C) CSFE+ hCD20+/3 hFcgRIIB+/3mFcgRII/ (target) and mFcgRII/ (non-
mAbs alone or in combination (0.2–0.4 mg/kg). Spleens were analyzed as above
(D) CFSE+ hCD20+/3 hFcgRIIB+/3mFcgRII/ (target) andmFcgRII/ (non-ta
Mice receivedWT 6G11 (23 20mg/kg) followed byRit (0.2–2mg/kg) and the ratio
independent experiments.
(A–D) Each dot depicts a result from an individual mouse, with mean ratios indic
(E and F) hCD20+/3 hFcgRIIB+/3mFcgRII/mice received either Rit ±WT or
the number of circulating B cells assessed over time. (E) Representative dot plo
injection. Numbers in the upper right quadrants indicate percent B cells compared
with Rit ± WT 6G11; top right graph indicates depletion of circulating B cells with
B cells with Rit (m2a; 4 mg/kg) ± 6G11 (mIgG1; 20 mg/kg). Means + SD of percen
up to 12 mice/group combined from at least two independent experiments. Two
See also Figure S5.bridging on the B cell surface, resulting in internalization of the
mAb:CD20:FcgRIIB complex (Lim et al., 2011; Vaughan et al.,
2014), limiting its ability to engage key Fc-dependent effector
functions. This mechanism is relevant for several different
targets, because mAbs to other surface receptors are also inter-
nalized in an hFcgRIIB-dependent manner (Pallasch et al., 2014;
Vaughan et al., 2014). Here, we describe the generation of fully
human hFcgRIIB mAbs that are able to block both of these
resistance mechanisms and are thus able to unleash the full
potential of other therapeutic mAbs and help overcome resis-
tance to mAb therapy in vivo.
Co-administration of hFcgRIIB mAb did not only improve OR
and CR responses inmice engrafted with CLL cells from patients
with rituximab-responsive disease, but also overcame the mAb
treatment-resistant phenotype of CLL cells from patients with
relapsed/refractory disease resistant to rituximab, ofatumumab,
or alemtuzumab. A role for tumor cell FcgRIIB was recently
proposed in resistance to hCD52 mAb therapy in select micro-
environments (Pallasch et al., 2014). hFcgRIIB was upregulated
in alemtuzumab-resistant bone marrow leukemic B cells
compared with more susceptible splenic compartments, and
shRNA-mediated knock-down of hFcgRIIB in these cells
improved hCD52 mAb therapy in otherwise resistant tissue.
These findings are consistent with the observations made in
our CLL model. Whereas CLL cells in susceptible peritoneal
compartments were readily depleted by hCD20 mAb, depletion
in resistant microenvironments required blocking of tumor
FcgRIIB. Consistent with high FcgRIIB expression underlying
decreased mAb activity in resistant tissue compartments,
FcgRIIB-blocking enhanced alemtuzumab and also type II
hCD20 mAb in our CLL model. We previously showed that
type II hCD20 mAbs only internalize efficiently in the presence
of high levels of FcgRIIB (Vaughan et al., 2014). Collectively,
these observations demonstrate that FcgRIIB-mediated resis-
tance is relevant to several different clinically approved anti-
bodies, indicating a broad therapeutic potential for combination
with hFcgRIIB mAb.
FcgRIIB-mAb combination was also relevant to different
tumor types, with co-administration of 6G11 boosting rituximab
antitumor activity in both CLL and MCL models in vivo. These
findings provide in vivo-proof-of-concept and solidify our previ-
ous observations (Lim et al., 2011) identifying FcgRIIB-mediatedAb Depletion of B Cells
cytes labeled with high or low levels of CFSE, respectively, were adoptively
, as indicated, and circulating (A) or splenic (B) cells were analyzed to determine
given a ratio of 1.0. Data combined from at least two independent experiments.
target) splenocytes were injected (i.v.) into WT recipient mice and injected with
. Data combined from at least three independent experiments.
rget) splenocytes were injected into hFcgRIIB+/3mFcgRII/ recipient mice.
of splenic CD19+ cells determined, as above. Data combined from at least three
ated by the horizontal line. One-way ANOVA performed.
N297Q 6G11 (20mg/kg) or 10mg/kg of each mAb in combination on day 0 and
ts analyzing circulatory B cells indicating pre-treatment and day 2 post-mAb
to pre-treatment levels. (F) Left graph indicating depletion of circulating B cells
Rit ± WT or N297Q 6G11; lower right graph indicates depletion of circulating
t circulating B cells post-treatment, normalized to pre-treatment levels, shown;
-way ANOVA performed.
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mAb internalization as a common mechanism underlying resis-
tance in different B cell cancers and individuals.
Considering additional potential mechanisms of action, we
demonstrate that hFcgRIIBmAbs have intrinsic anti-tumor activ-
ity. Veri et al. previously developed hFcgRIIB-specific mAbs but
did not examine their activity against cancer targets in vivo (Veri
et al., 2007). Rankin et al. subsequently showed that targeting
hFcgRIIB on malignant human B cell lines could be efficacious
as a monotherapy. However, this study (Rankin et al., 2006)
used xenograft systems, where the target antigen was ex-
pressed only on the tumor, and not critical immune effectors,
precluding assessment of the net effects of hFcgRIIB mAb. In
the current work, using two different mAbs (6G11 and AT10),
we demonstrate in immunocompetent syngeneic mouse models
where hFcgRIIB is expressed on both the target B cells and
effectors, that antagonistic hFcgRIIB mAbs have intrinsic target
cell depleting activity.
At least three distinct mechanisms may thus contribute to
the overall in vivo therapeutic activity of 6G11: intrinsic cytotox-
icity, prevention of therapeutic mAb internalization, and neutral-
ization of FcgRIIB-inhibitory signaling in immune cells. Several
observations suggest that blocking receptor internalization and
inhibitory signaling are the most critical for overcoming drug
resistance. First, there was a pronounced and apparently syner-
gistic effect when antagonistic hFcgRIIB and hCD20 mAbs were
co-administrated to the mice where hFcgRIIB is expressed on
both target and effector cells. Second, we found that whereas
B cell deletion was inefficient with AT10 alone, the combination
of AT10 and rituximab was effective in augmenting rituximab
activity. Most definitively, our data with N297Q hIgG1 6G11,
which lacks the ability to engage activatory FcgR and has no
direct cytotoxic capacity, confirms that blocking FcgRIIB activ-
ity is the key mechanism behind the efficacy of this approach.
This provides evidence that function-blocking mAbs to FcgRIIB
can recapitulate the enhanced anti-cancer mAb responses
observed following genetic deletion of FcgRIIB (Clynes et al.,
2000). However, here we have not explored directly the relative
importance of antagonizing FcgRIIB function on the target
versus immune effector cells for activity; these studies form
the basis of our ongoing endeavors.
Of note, it has long been appreciated that CLL is sub-optimally
treated with rituximab (O’Brien et al., 2001) and ofatumumab
(Coiffier et al., 2006, 2008) with higher doses being required.
Coupled to our previous data, our current results indicate thatFigure 6. hFcgRIIB mAb 6G11 Potentiates Therapeutic mAb Depletion
(A and B) The spleen of a NOD/SCID mouse engrafted with primary CLL cells fr
primary mAb.
(C) Mice xenografted with human CLL cells (n = 11 patients) were treated with 1–
cells remaining in the spleen enumerated and normalized to the proportion after
(D) Mice xenografted with CLL cells from patients previously designated as refra
(E) CFSE+ hCD20+/3 hFcgRIIB+/3mFcgRII/ (target) andmFcgRII/ (non-ta
6G11 alone or in combination (0.008 mg/kg) and assessed for deletion in the spl
(F) CFSE+ hCD20+/3 hFcgRIIB+/3mFcgRII/ (target) and mFcgRII/ (non-t
and treated with either WT iso ctrl or 6G11 (20 mg/kg), followed by GA101gly (0.0
(G) Mice engrafted with CLL cells (n = 4 patients) were treated with GA101 (0.2 m
(H) Mice engrafted with CLL cells (n = 3 patients) were treated with alemtuzumab (
Pie charts represent the number of NR (black), OR (blue), and CR (green) primar
(C–H) Each dot depicts an individual mouse, with mean ratios indicated by the hor
a permutation statistical test. See also Figure S6 and Tables S3 and S4.combination therapy with hFcgRIIB mAb may not only be a
way of preventing resistance, but perhaps also of decreasing
the dose or shortening duration of hCD20 mAb therapy.
In addition to affording significant activity, a therapeutic mAb
must be tolerable and have therapeutically relevant PK. The
high specificity of 6G11 for hFcgRIIB, with its lack of binding to
hFcgRIIA, and negligible cross-reactivity with animal species
commonly used for toxicological studies, prompted us to
investigate safety parameters and PK/pharmacodynamics (PD)
in mice expressing hFcgRIIB at levels and on cell types and
tissues similar to those of humans. These studies indicated
that 6G11 was well tolerated with a therapeutically relevant PK
profile typical for a hIgG1 mAb with an estimated half-life of
weeks in man.
Interestingly, in both human blood and in vivo in hFcgRIIB Tg
mice, 6G11 treatment resulted in specific deletion of B cells.
Although monocytes in both systems express hFcgRIIB, they
were not substantially deleted. Current evidence suggests that
macrophages and/or monocytes are the key effector cells
responsible for mAb therapy (Beers et al., 2010; Biburger et al.,
2011; Gu¨l et al., 2014) and so our data indicate that the key effec-
tors are not deleted by hFcgRIIB mAb.
We previously explored an equivalent panel of mFcgRII-spe-
cific mAbs (Williams et al., 2012) and observed that they had
limited therapeutic benefit due to their rapid consumption in vivo
(Williams et al., 2013b). Similar rates of internalization were not
seen on human target cells, at least in vitro, in agreement with
earlier studies (Rankin et al., 2006). Here, we extended these
observations and demonstrated that on primary human CLL
samples and in mice expressing hFcgRIIB, rapid and extensive
mAb consumption was not observed. These data confirm our
earlier supposition that mouse and human inhibitory FcgRIIB
have different properties in relation to their capacity for internal-
ization and to function as an antigenic sink, and support that
hFcgRIIB is a pharmacodynamically and therapeutically relevant
target in humans.
Collectively, our results demonstrate in vivo proof-of-concept
that hFcgRIIB mAbs overcome the intrinsic and acquired resis-
tance of tumor cells to mAb drugs, and can restore responsive-
ness to mAb therapy in relapsed/refractory tumors. These data
support the clinical development of hFcgRIIB mAbs for therapy
of FcgRIIB-expressing B cell cancers. Furthermore, analogous
to the spread of CD20 mAbs into other diseases, there is evi-
dence to suggest their utility in other therapeutic settings suchof Normal and Malignant Target Cells In Vivo
om a patient was assessed by immunofluorescence (A) or by IHC (B); ctrl, no
10 mg/kg of hCD20 mAb (Rit), hFcgRIIB mAb (6G11), or both and percent CLL
treatment with iso ctrl.
ctory (n = 4 patients) were treated and assessed as in (C).
rget) splenocytes were injected (i.v.) intoWTmice and treated with GA101gly or
een as before. Data combined from two to three independent experiments.
arget) splenocytes were injected into hFcgRIIB+/3mFcgRII/ recipient mice
4 mg/kg) and analyzed as in (E).
g/kg), 6G11 (1 mg/kg), or both and assessed as in (C).
Alem; 1mg/kg), 6G11 (1 mg/kg), or both and assessed as in (C). (C, D, G, and H)
y patient CLL-bearing mice following mAb therapy, as defined in Table 1.
izontal line. (E and F) Data analyzed using one-way ANOVA and (C, D, G, and H)












































































































































































































































































































































































































































































































































































































































































































































































































































































































486 Cancer Cell 27, 473–488, April 13, 2015 ª2015 Elsevier Inc.as autoimmunity where FcgRIIB-expressing targets may be
amenable to manipulation, for example in systemic light-chain
amyloidosis where the target PCs express high levels of FcgRIIB
(Zhou et al., 2008) and rheumatoid arthritis where B cell activa-
tion might be reduced through agonism of FcgRIIB (Baerenwaldt
et al., 2011; Mauri and Jury, 2010). Clinical investigations in all
of these areas are now warranted. We aim to develop this
approach as a first-in-human clinical trial in combination with
rituximab in non-Hodgkin lymphoma patients later this year.EXPERIMENTAL PROCEDURES
Animals
Human (h) CD20 Tg, g-chain/ and mouse (m) FcgRIIB/ mice have been
described previously (Beers et al., 2008) with genotypes confirmed by PCR
and/or flow cytometry. CB-17 SCID and NOD/SCID mice were purchased
from Charles River and Taconic, respectively and then bred and maintained
in local animal facilities. Mice were bred and maintained in local facilities
in accordance with the UK Home Office and Swedish Board of Agriculture
guidelines. Animal experiments were regulated through local ethical commit-
tees and were performed under Home Office licenses (PPL30/1269 and
M90-11) and BioInvent general permit allowing animal work (31-11587/10).
Clinical Samples and Ethics
Ethical approval for the use of clinical sampleswas obtained by the Southamp-
ton University Hospitals NHS Trust from the Southampton and South West
Hampshire Research Ethics Committee or by the Ethics Committee of Ska˚ne
University Hospital. Informed consent was provided in accordance with the
Declaration of Helsinki. Samples were released from the Human Tissue
Authority licensed University of Southampton, Cancer Science Unit Tissue
Bank or obtained through the Department of Hematology and Department of
Oncology at Ska˚nes University Hospital, Lund.
Generation of hFcgRIIB mAb
hFcgRIIB mAbs were identified by screening the n-CoDeR scFv phage
display library using the extracellular domain of hFcgRIIB and hFcgRIIA fused
to mIgG3-Fc (hFcgRIIB/A-Fc) as target and non-target, respectively. Full
details in are provided in the Supplemental Experimental Procedures.
Immunotherapy In Vivo
Subcutaneous Models
Daudi (5 3 106) were injected subcutaneously with growth factor reduced
Matrigel (BD Biosciences) into SCID mice and subsequently treated with
mAb on days 7, 14, 21, and 28. Tumor growth was calculated as [weight
(mg) = (length 3 width2)/2].
Adoptive Transfer
This procedure was performed as detailed elsewhere (Beers et al., 2010) and
in the Supplemental Experimental Procedures.
B Cell Depletion
Mice were given hCD20 or hFcgRIIB mAbs alone or in combination intra-
venously (i.v.) and leukocytes were assessed as described elsewhere (Beers
et al., 2010).
Primary Human Xenograft Models
Patients’ PBMCs were isolated and injected (6–10 3 107 cells) i.v. into
irradiated (1 Gy) mice. Four to five days later, mice were treated with mAbs
(intraperitoneally [i.p.]), with a second injection 2–3 days later and killed
2–3 days after that. Spleens were harvested, and human cells were identified
and quantified as CD45+ CD5+ CD19+.
PD, PK, and Immunogenicity Studies
hFcgRIIB+/ 3mFcgRII/ mice were injected with a single dose of WT 6G11
i.v. or i.p. or with multiple shots of 10 mg/kg. Mice were examined throughout
for signs of distress, weight loss, B cell numbers (CD19+ B220+), toxicity,
or pathology. Serum concentrations of 6G11 and MAHA were determined
as described in the Supplemental Experimental Procedures.
Statistical Analysis
To compare experimental groups, Wilcoxon, paired or unpaired t test analyses
were performed; Kaplan Meier curves were produced and analyzed by Log
rank test. For in vivo adoptive transfer assays containing more than two
groups, one- or two-way ANOVA were used. To evaluate the efficacy of
mAbs in the in vivo xenograft experiments, the percentages of tumor cells in
the spleens of treated animals were measured and the average difference
in percentage between animals xenografted with tumor cells from the same
patient were calculated. These differences were then averaged across pa-
tients to obtain a summary statistic that reflects the overall effect. To calculate
the distribution of this statistical test under the null hypothesis, we used a
permutation approach where test group labels were randomly reassigned
within patients. One billion permutations were used. This approach does
not make any parametric or other distributional assumptions and ensures a
p value resolution of 1 3 109. As a complement to this approach, we used
standard parametric tests (one-way ANOVA), which yielded similar results.
For differences in OR and CR, Chi-square tests were used. Statistical analysis
was performed using GraphPadPrism (v5 or 6). Stars denote significance
as follows: *p % 0.05, **p % 0.01, ***p % 0.001, and ****p % 0.0001, unless
otherwise stated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.03.005.
AUTHOR CONTRIBUTIONS
A.R. and I.T. performed research, analyzed and interpreted data, and helped
write the manuscript; L.M., K.L.C., M.K., A.L., J.M., A.S., A.T.V, V.S., N.S,
B.S., H.T.C., Z.L., E.L.W., G.M, R.J.O., C.I.M., S.A.J., L.N.D., K.H., and B.N.
all generated or provided key reagents or performed and analyzed research;
J.S.V., G.J., M.H., and M.J. contributed key reagents and to discussion of
the data; A.D., S.A.B., P.W.M.J., and M.J.G. discussed and interpreted data
and edited the manuscript; B.F. and M.S.C. designed the study, analyzed
and interpreted data, and wrote the manuscript.
ACKNOWLEDGMENTS
We are grateful to all patients and volunteers who generously donated their
biological specimens for research, and Drs. F. Forconi, A. Duncombe, K.
Potter, A. Steele, I. Tracy, and I. Wheatley for provision and assistance with
clinical material. We would like to thank colleagues from the Cancer Sciences
Unit who provided advice and technical support, including A. Tutt, R. French,
C. Lee; P. Duriez (Protein Core Facility) for production of recombinant M-CSF;
and the Biomedical Research Facility for animal husbandry. Funding was pro-
vided by Leukaemia and Lymphoma Research grants 08014, 08048, 09009,
and 12009; and CRUK grants C1477/A10834 and C34999/A18087.
I.T., B.F., L.M., M.K., A.L., J.M., A.S., and Z.L. are or were employees of
BioInvent International during their contribution to this paper. G.M. received
funding from BioInvent. M.S.C. acts as a consultant to BioInvent and Roche
and has received institutional support from BioInvent for grants and patents.
M.J.G. receives an institutional grant from Cancer Research UK, acts as a
consultant to a number of biotech companies to write general antibody expert
reports, and receives institutional payments and royalties from antibody
patents and licenses. P.W.M.J. acts as a consultant to Roche and Pfizer and
has received payments for lectures from Millennium Takeda and Pfizer.
Received: June 27, 2014
Revised: November 19, 2014
Accepted: March 10, 2015
Published: April 13, 2015
REFERENCES
Baerenwaldt, A., Lux, A., Danzer, H., Spriewald, B.M., Ullrich, E., Heidkamp,
G., Dudziak, D., and Nimmerjahn, F. (2011). Fcg receptor IIB (FcgRIIB) main-tains humoral tolerance in the human immune system in vivo. Proc. Natl.
Acad. Sci. USA 108, 18772–18777.
Bardelli, A., and Siena, S. (2010). Molecular mechanisms of resistance to ce-
tuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254–1261.
Beers, S.A., Chan, C.H., James, S., French, R.R., Attfield, K.E., Brennan, C.M.,
Ahuja, A., Shlomchik, M.J., Cragg, M.S., and Glennie, M.J. (2008). Type II
(tositumomab) anti-CD20 monoclonal antibody out performs type I (rituxi-
mab-like) reagents in B-cell depletion regardless of complement activation.
Blood 112, 4170–4177.
Beers, S.A., French, R.R., Chan, H.T., Lim, S.H., Jarrett, T.C., Vidal, R.M.,
Wijayaweera, S.S., Dixon, S.V., Kim, H., Cox, K.L., et al. (2010). Antigenic
modulation limits the efficacy of anti-CD20 antibodies: implications for anti-
body selection. Blood 115, 5191–5201.
Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H.,
Woigk,M., Dudziak, D., and Nimmerjahn, F. (2011). Monocyte subsets respon-
sible for immunoglobulin G-dependent effector functions in vivo. Immunity 35,
932–944.
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat,
P., and Watier, H. (2002). Therapeutic activity of humanized anti-CD20 mono-
clonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Blood 99, 754–758.
Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory Fc
receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6,
443–446.
Coiffier, B., Tilly, H., Pedersen, L.M., Plesner, T., Frederiksen, H., van Oers,
M.H.J., Wooldridge, J., Kloczko, J.S., Holowiecki, J., Hellmann, A., et al.
(2006). Significant correlation between survival endpoints and exposure to
ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood 108,
2842.
Coiffier, B., Lepretre, S., Pedersen, L.M., Gadeberg, O., Fredriksen, H., van
Oers, M.H., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., et al.
(2008). Safety and efficacy of ofatumumab, a fully human monoclonal anti-
CD20 antibody, in patients with relapsed or refractory B-cell chronic lympho-
cytic leukemia: a phase 1-2 study. Blood 111, 1094–1100.
Cragg, M.S., Morgan, S.M., Chan, H.T., Morgan, B.P., Filatov, A.V., Johnson,
P.W., French, R.R., and Glennie, M.J. (2003). Complement-mediated lysis by
anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045–
1052.
Dyer, M.J., Hale, G., Hayhoe, F.G., and Waldmann, H. (1989). Effects of
CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influ-
ence of antibody isotype. Blood 73, 1431–1439.
Greenman, J., Tutt, A.L., George, A.J., Pulford, K.A., Stevenson, G.T., and
Glennie, M.J. (1991). Characterization of a new monoclonal anti-Fc gamma
RII antibody, AT10, and its incorporation into a bispecific F(ab’)2 derivative
for recruitment of cytotoxic effectors. Mol. Immunol. 28, 1243–1254.
Gu¨l, N., Babes, L., Siegmund, K., Korthouwer, R., Bo¨gels, M., Braster, R.,
Vidarsson, G., ten Hagen, T.L., Kubes, P., and van Egmond, M. (2014).
Macrophages eliminate circulating tumor cells after monoclonal antibody ther-
apy. J. Clin. Invest. 124, 812–823.
Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., and Tedder, T.F. (2006).
Antibody isotype-specific engagement of Fcgamma receptors regulates B
lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203,
743–753.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next gener-
ation. Cell 144, 646–674.
Hussain, K., Hargreaves, C.E., Roghanian, A., Oldham, R.J., Chan, H.T.,
Mockridge, C.I., Chowdhury, F., Frende´us, B., Harper, K.S., Strefford, J.C.,
et al. (2015). Upregulation of FcgRIIb on monocytes is necessary to promote
the superagonist activity of TGN1412. Blood 125, 102–110.
Lee, C.S., Ashton-Key, M., Cogliatti, S., Rondeau, S., Schmitz, S.F., Ghielmini,
M., Cragg, M.S., and Johnson, P. (2015). Expression of the inhibitory Fc
gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers
the response rate to rituximab monotherapy (SAKK 35/98). Br. J. Haematol.
168, 145–148.Cancer Cell 27, 473–488, April 13, 2015 ª2015 Elsevier Inc. 487
Lim, S.H., Beers, S.A., French, R.R., Johnson, P.W., Glennie, M.J., and Cragg,
M.S. (2010). Anti-CD20 monoclonal antibodies: historical and future perspec-
tives. Haematologica 95, 135–143.
Lim, S.H., Vaughan, A.T., Ashton-Key, M., Williams, E.L., Dixon, S.V., Chan,
H.T., Beers, S.A., French, R.R., Cox, K.L., Davies, A.J., et al. (2011). Fc gamma
receptor IIb on target B cells promotes rituximab internalization and reduces
clinical efficacy. Blood 118, 2530–2540.
Mauri, C., and Jury, E.C. (2010). Could the expression of CD86 and FcgRIIB on
B cells be functionally related and involved in driving rheumatoid arthritis?
Arthritis Res. Ther. 12, 133.
Minard-Colin, V., Xiu, Y., Poe, J.C., Horikawa, M., Magro, C.M., Hamaguchi,
Y., Haas, K.M., and Tedder, T.F. (2008). Lymphoma depletion during CD20
immunotherapy in mice is mediated by macrophage FcgammaRI,
FcgammaRIII, and FcgammaRIV. Blood 112, 1205–1213.
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M.,
Salido, M., Gallen, M., Marsters, S., Tsai, S.P., et al. (2012). Identification of a
mutation in the extracellular domain of the Epidermal Growth Factor Receptor
conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221–223.
Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N., and
Bousso, P. (2013). The mechanism of anti-CD20-mediated B cell depletion re-
vealed by intravital imaging. J. Clin. Invest. 123, 5098–5103.
Nimmerjahn, F., and Ravetch, J.V. (2008). Fcgamma receptors as regulators of
immune responses. Nat. Rev. Immunol. 8, 34–47.
Nimmerjahn, F., and Ravetch, J.V. (2011). FcgRs in health and disease. Curr.
Top. Microbiol. Immunol. 350, 105–125.
O’Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes,
J., Lerner, S., and Keating, M.J. (2001). Rituximab dose-escalation trial in
chronic lymphocytic leukemia. J. Clin. Oncol. 19, 2165–2170.
Pallasch, C.P., Leskov, I., Braun, C.J., Vorholt, D., Drake, A., Soto-Feliciano,
Y.M., Bent, E.H., Schwamb, J., Iliopoulou, B., Kutsch, N., et al. (2014).
Sensitizing protective tumor microenvironments to antibody-mediated ther-
apy. Cell 156, 590–602.
Rampias, T., Giagini, A., Siolos, S., Matsuzaki, H., Sasaki, C., Scorilas, A., and
Psyrri, A. (2014). RAS/PI3K crosstalk and cetuximab resistance in head and
neck squamous cell carcinoma. Clin. Cancer Res 20, 2933–2946.
Rankin, C.T., Veri, M.C., Gorlatov, S., Tuaillon, N., Burke, S., Huang, L.,
Inzunza, H.D., Li, H., Thomas, S., Johnson, S., et al. (2006). CD32B, the human
inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy
of B-cell lymphoma. Blood 108, 2384–2391.
Ravetch, J.V., and Perussia, B. (1989). Alternative membrane forms of Fc
gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-spe-
cific expression of two genes that differ in single nucleotide substitutions.
J. Exp. Med. 170, 481–497.
Reichert, J.M., and Dhimolea, E. (2012). The future of antibodies as cancer
drugs. Drug Discov. Today 17, 954–963.
Rezvani, A.R., and Maloney, D.G. (2011). Rituximab resistance. Best Pract.
Res. Clin. Haematol. 24, 203–216.
Ro¨mer, P.S., Berr, S., Avota, E., Na, S.Y., Battaglia, M., ten Berge, I., Einsele,
H., and Hu¨nig, T. (2011). Preculture of PBMCs at high cell density increases488 Cancer Cell 27, 473–488, April 13, 2015 ª2015 Elsevier Inc.sensitivity of T-cell responses, revealing cytokine release by CD28 superagon-
ist TGN1412. Blood 118, 6772–6782.
So¨derlind, E., Strandberg, L., Jirholt, P., Kobayashi, N., Alexeiva, V., Aberg,
A.M., Nilsson, A., Jansson, B., Ohlin, M., Wingren, C., et al. (2000).
Recombining germline-derived CDR sequences for creating diverse single-
framework antibody libraries. Nat. Biotechnol. 18, 852–856.
Tao, M.H., and Morrison, S.L. (1989). Studies of aglycosylated chimeric
mouse-human IgG. Role of carbohydrate in the structure and effector func-
tions mediated by the human IgG constant region. J. Immunol. 143, 2595–
2601.
Vaughan, A.T., Iriyama, C., Beers, S.A., Chan, C.H., Lim, S.H., Williams, E.L.,
Shah, V., Roghanian, A., Frende´us, B., Glennie, M.J., and Cragg, M.S.
(2014). Inhibitory FcgRIIb (CD32b) becomes activated by therapeutic mAb in
both cis and trans and drives internalization according to antibody specificity.
Blood 123, 669–677.
Veri, M.C., Gorlatov, S., Li, H., Burke, S., Johnson, S., Stavenhagen, J., Stein,
K.E., Bonvini, E., and Koenig, S. (2007). Monoclonal antibodies capable of
discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the
activating Fcgamma-receptor IIA (CD32A): biochemical, biological and func-
tional characterization. Immunology 121, 392–404.
Weiner, L.M., Surana, R., and Wang, S. (2010). Monoclonal antibodies: versa-
tile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327.
Weng, W.K., and Levy, R. (2003). Two immunoglobulin G fragment C receptor
polymorphisms independently predict response to rituximab in patients with
follicular lymphoma. J. Clin. Oncol. 21, 3940–3947.
Williams, E.L., Tutt, A.L., French, R.R., Chan, H.T., Lau, B., Penfold, C.A.,
Mockridge, C.I., Roghanian, A., Cox, K.L., Verbeek, J.S., et al. (2012).
Development and characterisation of monoclonal antibodies specific for the
murine inhibitory FcgRIIB (CD32B). Eur. J. Immunol. 42, 2109–2120.
Williams, E.L., Lim, S.H., Beers, S.A., Johnson, P.W., Strefford, J.C., Glennie,
M.J., and Cragg, M.S. (2013a). Overcoming resistance to therapeutic anti-
bodies by targeting Fc Receptors. Resistance to Immunotherapeutic
Antibodies in Cancer. Strategies to Overcome Resistance Pubs Springer 2,
49–71.
Williams, E.L., Tutt, A.L., Beers, S.A., French, R.R., Chan, C.H., Cox, K.L.,
Roghanian, A., Penfold, C.A., Butts, C.L., Boross, P., et al. (2013b).
Immunotherapy targeting inhibitory Fcg receptor IIB (CD32b) in the mouse is
limited by monoclonal antibody consumption and receptor internalization.
J. Immunol. 191, 4130–4140.
Wong, A.L., and Lee, S.C. (2012). Mechanisms of Resistance to Trastuzumab
and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int. J.
Breast Cancer 2012, 415170.
Zhou, P., Comenzo, R.L., Olshen, A.B., Bonvini, E., Koenig, S., Maslak, P.G.,
Fleisher, M., Hoffman, J., Jhanwar, S., Young, J.W., et al. (2008). CD32B is
highly expressed on clonal plasma cells frompatients with systemic light-chain
amyloidosis and provides a target for monoclonal antibody-based therapy.
Blood 111, 3403–3406.
